克拉霉素、阿奇霉素和红霉素对伯氏疏螺旋体的体外比较活性
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
作者信息
Dever L L, Jorgensen J H, Barbour A G
机构信息
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7881.
出版信息
Antimicrob Agents Chemother. 1993 Aug;37(8):1704-6. doi: 10.1128/AAC.37.8.1704.
Abstract
The in vitro activities of the macrolide antibiotics clarithromycin, 14-hydroxy-clarithromycin, azithromycin, and erythromycin against 19 isolates of Borrelia burgdorferi were investigated. MICs ranged from 0.003 to 0.03 microgram of clarithromycin per ml, 0.007 to 0.03 microgram of 14-hydroxyclarithromycin per ml, 0.003 to 0.03 microgram of azithromycin per ml, and 0.007 to 0.06 microgram of erythromycin per ml. Time-kill studies using the B31 strain of B. burgdorferi demonstrated a > or = 3-log10-unit killing after 72 h with each of the macrolide antibiotics tested in concentrations representing twice the respective MICs.
摘要
对大环内酯类抗生素克拉霉素、14-羟基克拉霉素、阿奇霉素和红霉素针对19株伯氏疏螺旋体的体外活性进行了研究。克拉霉素的最低抑菌浓度（MIC）范围为每毫升0.003至0.03微克，14-羟基克拉霉素为每毫升0.007至0.03微克，阿奇霉素为每毫升0.003至0.03微克，红霉素为每毫升0.007至0.06微克。使用伯氏疏螺旋体B31菌株进行的时间-杀菌研究表明，在72小时后，所测试的每种大环内酯类抗生素在两倍于各自MIC的浓度下均有≥3个对数10单位的杀菌效果。
相似文献
1
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.克拉霉素、阿奇霉素和红霉素对伯氏疏螺旋体的体外比较活性
Antimicrob Agents Chemother. 1993 Aug;37(8):1704-6. doi: 10.1128/AAC.37.8.1704.
2
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.通过最低抑菌浓度（MIC）和时间杀菌曲线研究20株对青霉素敏感及耐药的肺炎球菌对左氧氟沙星、环丙沙星、氧氟沙星、红霉素、阿奇霉素和克拉霉素的敏感性。
Diagn Microbiol Infect Dis. 1997 Jul;28(3):131-7. doi: 10.1016/s0732-8893(97)00017-5.
3
In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.新型大环内酯类药物罗他霉素对伯氏疏螺旋体的体外活性
Antimicrob Agents Chemother. 1995 May;39(5):1185-6. doi: 10.1128/AAC.39.5.1185.
4
Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.1967 - 2015年在捷克共和国分离出的百日咳博德特氏菌菌株对红霉素、克拉霉素、阿奇霉素、环丙沙星和甲氧苄啶/磺胺甲恶唑的最低抑菌浓度趋势
Cent Eur J Public Health. 2017 Dec;25(4):282-286. doi: 10.21101/cejph.a4948.
5
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.克拉霉素、红霉素和阿奇霉素对青霉素敏感及耐药肺炎球菌的比较活性
Antimicrob Agents Chemother. 1996 Aug;40(8):1950-2. doi: 10.1128/AAC.40.8.1950.
6
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.伯氏疏螺旋体的体外抗菌药敏试验：微量稀释法测定最低抑菌浓度及时间杀菌研究
J Clin Microbiol. 1992 Oct;30(10):2692-7. doi: 10.1128/jcm.30.10.2692-2697.1992.
7
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.与对红霉素、阿奇霉素、克拉霉素、罗红霉素和克林霉素的敏感性相比，青霉素敏感和耐药肺炎球菌对地红霉素的敏感性。
Antimicrob Agents Chemother. 1997 Sep;41(9):1867-70. doi: 10.1128/AAC.41.9.1867.
8
Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.化脓性链球菌对阿奇霉素、克拉霉素、红霉素和罗红霉素的体外敏感性
J Med Microbiol. 1995 Nov;43(5):386-91. doi: 10.1099/00222615-43-5-386.
9
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.两种新型大环内酯类药物GW 773546和GW 708408与红霉素、阿奇霉素、克拉霉素、克林霉素和泰利霉素相比的抗肺炎球菌活性。
Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12. doi: 10.1128/AAC.48.11.4103-4112.2004.
10
In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.伯氏疏螺旋体对11种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 1993 Jul;37(7):1444-6. doi: 10.1128/AAC.37.7.1444.
引用本文的文献
1
Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis.缩短莱姆病抗生素治疗疗程的研究：一项系统评价与荟萃分析
Infection. 2025 Apr 17. doi: 10.1007/s15010-025-02501-3.
2
The In Vitro Antimicrobial Susceptibility of sensu lato: Shedding Light on the Known Unknowns.广义的体外抗菌药敏性：揭示已知的未知因素。
Pathogens. 2023 Sep 28;12(10):1204. doi: 10.3390/pathogens12101204.
3
Evaluation of Disulfiram Drug Combinations and Identification of Other More Effective Combinations against Stationary Phase .双硫仑药物组合的评估以及其他针对稳定期更有效组合的鉴定。
Antibiotics (Basel). 2020 Aug 26;9(9):542. doi: 10.3390/antibiotics9090542.
4
Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.酮内酯类、大环内酯类和氮杂内酯类药物对螺旋体伯氏疏螺旋体的体外活性比较。
Antimicrob Agents Chemother. 2004 Jan;48(1):344-7. doi: 10.1128/AAC.48.1.344-347.2004.
5
Diagnosis, treatment, and prevention of Lyme disease in children.儿童莱姆病的诊断、治疗与预防
Paediatr Drugs. 2003;5(6):363-72. doi: 10.2165/00128072-200305060-00002.
6
Erythromycin resistance in Borrelia burgdorferi.伯氏疏螺旋体对红霉素的耐药性。
Antimicrob Agents Chemother. 2002 Nov;46(11):3637-40. doi: 10.1128/AAC.46.11.3637-3640.2002.
7
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.住院儿科患者常用的抗菌和抗真菌药物：基于临床药代动力学对治疗的影响
Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003.
8
Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.抗微生物治疗对小鼠伯氏疏螺旋体感染的有效性。
Antimicrob Agents Chemother. 1994 Jul;38(7):1567-72. doi: 10.1128/AAC.38.7.1567.
9
In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.新型大环内酯类药物罗他霉素对伯氏疏螺旋体的体外活性
Antimicrob Agents Chemother. 1995 May;39(5):1185-6. doi: 10.1128/AAC.39.5.1185.
本文引用的文献
1
In vitro inhibition of Borrelia burgdorferi growth by antibodies.抗体对伯氏疏螺旋体生长的体外抑制作用。
J Infect Dis. 1993 Jan;167(1):165-72. doi: 10.1093/infdis/167.1.165.
2
Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria.革兰氏阴性肠道细菌对阿奇霉素、克拉霉素和罗红霉素的外膜通透性屏障
Antimicrob Agents Chemother. 1993 Feb;37(2):354-6. doi: 10.1128/AAC.37.2.354.
3
Treatment of the early manifestations of Lyme disease.莱姆病早期表现的治疗。
Ann Intern Med. 1983 Jul;99(1):22-6. doi: 10.7326/0003-4819-99-1-22.
4
New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.大环内酯类抗生素的新方向：药代动力学与临床疗效
Antimicrob Agents Chemother. 1989 Sep;33(9):1419-22. doi: 10.1128/AAC.33.9.1419.
5
A perspective on the treatment of Lyme borreliosis.
Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1518-25. doi: 10.1093/clinids/11.supplement_6.s1518.
6
Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo.螺旋体的分离技术及其在体外和体内对抗生素的敏感性。
Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1505-10. doi: 10.1093/clinids/11.supplement_6.s1505.
7
Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.
Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651-3. doi: 10.1007/BF01968150.
8
The pharmacokinetics of azithromycin in human serum and tissues.阿奇霉素在人血清和组织中的药代动力学。
J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82. doi: 10.1093/jac/25.suppl_a.73.
9
Lyme disease: recommendations for diagnosis and treatment.莱姆病：诊断与治疗建议
Ann Intern Med. 1991 Mar 15;114(6):472-81. doi: 10.7326/0003-4819-114-6-472.
10
The development of macrolides: clarithromycin in perspective.大环内酯类药物的发展：克拉霉素的前景展望
J Antimicrob Chemother. 1991 Feb;27 Suppl A:1-9. doi: 10.1093/jac/27.suppl_a.1.
Zotero 插件